Their observation that ACE2 expression is induced by type I IFNs in primary upper airway basal cells and lung tissue is hard to reconcile with IFNs inhibiting infection by SARS-CoV-2, yet recent emerging data suggesting a role for the renin-angiotensin pathway in protection from specific clinical features of COVID-19 would support a role for ACE2 in limiting COVID-19 severity. The gene discussed is ACE2; the disease is COVID-19.